Effect of Low-intensity Transcranial Focused Ultrasound Stimulation on Neuropathic Pain: Protocol for a Randomised, Single-blind, Placebo-controlled, Three-arm, Parallel-group Pilot Trial (TUS-P-02 Study)

Nobuhiko Mori, Yuhei Hoshikuma, Koichi Hosomi, Akihiro Yamamoto, Takeshi Shimizu, Hui Ming Khoo, Naoki Tani, Satoru Oshino, Haruhiko KishimamedRxiv 2025 · DOI

Abstract

Neuropathic pain (NP) remains a significant clinical challenge, as conventional pharmacological therapies often provide limited relief and are frequently associated with intolerable side effects. While non-invasive neuromodulation techniques like repetitive transcranial magnetic stimulation (rTMS) have shown analgesic potential, their efficacy is often restricted by an inability to stimulate deeper brain regions. Low-intensity transcranial focused ultrasound stimulation (TUS) is an emerging technology that allows for the precise, non-invasive targeting of deep brain structures. This paper outlines the protocol for the TUS-P-02 study, a randomised, participant-blinded, placebo-controlled trial designed to evaluate the long-term therapeutic efficacy and safety of repeated TUS sessions in patients with chronic NP.

Introduction

Neuropathic pain, caused by a lesion or disease of the somatosensory nervous system, often leads to a significant decrease in quality of life. Current treatments are frequently inadequate. While high-frequency rTMS over the primary motor cortex (M1) is a recognized intervention, its magnetic fields cannot effectively reach deeper targets, such as the posterior superior insula (PSI) or the motor cortex regions associated with lower-limb pain.

Focused ultrasound (TUS) offers a unique solution by utilizing acoustic energy that can be focused through the skull onto specific deep-tissue targets with millimetre precision. This protocol describes the first clinical trial to investigate whether repeated TUS sessions can induce sustained "offline" analgesic effects in patients with NP.

Methods and Study Design

The TUS-P-02 study is a three-arm, parallel-group, participant-blinded pilot trial. A total of 39 participants with chronic NP (duration ≥ 3 months; pain intensity ≥ 4 on the Numerical Rating Scale) will be enrolled and randomly allocated to one of three groups:

  1. TUS targeting the Primary Motor Cortex (M1): A traditional neuromodulation target for pain.
  2. TUS targeting the Posterior Superior Insula (PSI): A deep-brain hub critical for pain perception and processing.
  3. Sham Stimulation: The device is positioned identically, but no ultrasound energy is delivered.

Technical Intervention

The study utilizes the NeuroFUS system, employing a four-element annular array transducer. To ensure precision, the Brainsight neuro-navigation system is used in conjunction with individual 3D-MRI scans for each participant.

Stimulation parameters are set at a frequency of 500 kHz with a 10% duty cycle (10 ms pulses at 10 Hz) for a total duration of 580 seconds per session. To adjust for individual skull thickness and target depth (typically 43–54 mm), specialized ultrasound gel pads of varying thicknesses are used. Participants undergo one session per week for a total of eight weeks to evaluate the cumulative effects of the treatment.

Outcome Measures

The primary outcome is the change in weekly average pain intensity scores, as recorded by participants in a daily pain diary using the Numerical Rating Scale (NRS).

Secondary outcomes include:

  • Pain Quality: Assessed via the Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2).
  • Psychological Impact: Measured using the Hospital Anxiety and Depression Scale (HADS).
  • Sensory Thresholds: Quantitative Sensory Testing (QST) to evaluate changes in thermal and vibration sensitivity.
  • Cortical Excitability: Motor cortical excitability is measured via TMS to provide physiological evidence of neural modulation.
  • Safety: Continuous monitoring for adverse events, adhering to the ITRUSST safety consensus (Mechanical Index of 1.32 and thermal dose below 0.25 CEM43).

Discussion and Key Insights

This trial addresses a critical gap in non-invasive brain stimulation: the "depth problem." By targeting the posterior superior insula, the study explores whether modulating deep pain-processing hubs can provide superior relief compared to superficial cortical stimulation. Furthermore, the use of TUS may overcome the anatomical hurdles that have previously made lower-limb neuropathic pain difficult to treat with rTMS.

As a pilot study, the sample size of 39 participants is powered to detect significant differences based on prior rTMS efficacy data. However, the study faces limitations, including the inability to blind the operators due to the technical requirements of the navigation system, and the inherent challenges of identifying the optimal "dose" for a relatively new technology.

Conclusion

The TUS-P-02 study represents a significant step forward in the search for non-surgical, non-pharmacological treatments for chronic pain. If TUS is shown to be safe and effective over an eight-week period, it could establish a new therapeutic category for patients who have exhausted conventional treatment options. Findings will be disseminated through peer-reviewed publications and scientific presentations upon the trial's completion.

Summary updated

Abstract

ABSTRACT Introduction Neuropathic pain (NP) remains difficult to manage because conventional pharmacological therapies often have limited efficacy and intolerable side effects. Non-invasive neuromodulation techniques have emerged as potential alternatives with fewer adverse effects. Meta-analyses of randomised controlled trials suggest that high-frequency repetitive transcranial magnetic stimulation over the primary motor cortex has analgesic effects; however, its efficacy is modest and restricted by the inability to stimulate deeper brain regions. Low-intensity transcranial focused ultrasound stimulation (TUS) is a novel approach that enables precise targeting of deep brain structures and modulation of neural activity. Although promising in preclinical and preliminary human studies, its long-term therapeutic efficacy for NP remains unknown. This trial aims to evaluate the therapeutic effects and safety of repeated TUS sessions in patients with NP. Methods and analysis This randomised, participant-blinded, placebo-controlled, three-arm, parallel-group clinical trial will enrol 39 participants with NP (pain duration ≥ 3 months; pain intensity ≥ 4 on the Numerical Rating Scale). Participants will be randomly allocated to one of three groups: (1) TUS targeting the primary motor cortex, (2) TUS targeting the posterior superior insula, or (3) sham stimulation. Each participant will undergo weekly sessions for eight weeks. The primary outcome is change in weekly average pain intensity scores recorded in a pain diary. Secondary outcomes include additional pain scales, quality of life measures, psychological assessments, quantitative sensory testing, motor cortical excitability, and adverse events. Ethics and dissemination The protocol has been approved by the University of Osaka Clinical Research Review Board. Written informed consent will be obtained from all participants. Findings will be disseminated via scientific presentations and peer-reviewed publications. Trial registration number jRCTs052240227 STRENGTHS AND LIMITATIONS OF THIS STUDY ⇒ This is the first randomised, participant-blinded, placebo-controlled clinical trial evaluating the long-term effects of transcranial focused ultrasound stimulation (TUS) for neuropathic pain. ⇒ TUS is a novel, non-invasive technique that can precisely target deep brain areas using a navigation system, offering the potential to modulate brain function. ⇒ The single-blind design (participants only) may introduce a risk of performance bias, as operators cannot be blinded owing to technical constraints. ⇒ The small sample size may limit statistical power to detect subtle between-group differences.
BibTeX
@misc{mori2025effect,
  author = {Nobuhiko Mori and Yuhei HOSHIKUMA and Koichi Hosomi and Akihiro Yamamoto and Takeshi Shimizu and Hui Ming Khoo and Naoki Tani and Satoru Oshino and Haruhiko Kishima},
  title = {{Effect of Low-intensity Transcranial Focused Ultrasound Stimulation on Neuropathic Pain: Protocol for a Randomised, Single-blind, Placebo-controlled, Three-arm, Parallel-group Pilot Trial (TUS-P-02 Study)}},
  year = {2025},
  doi = {10.1101/2025.11.05.25338279},
  howpublished = {medRxiv},
}
Figure